Skip to main content

Atara Biotherapeutics, Inc.

ATRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001604464

In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Atara Biotherapeutics, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of ATRA: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders139125−14
Shares97.3M102.7M+5.35M (+5.5%)
Value$319.3M$297.8M−$21.5M (−6.7%)

New holders (8)

Institutions that held Atara Biotherapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to ATRA in Q1 2023
InstitutionSharesValue% of portfolio
UBS Asset Management Americas Inc108,004$313.2K0.00%
Profund Advisors LLC104,484$303.0K0.02%
Shell Asset Management Co53,824$156.0K0.01%
Point72 Asset Management, L.P.27,258$79.0K0.00%
Lake Street Advisors Group, LLC11,560$34.0K0.00%
Captrust Financial Advisors10,306$29.9K0.00%
Russell Investments Group, Ltd.5,711$16.6K0.00%
Cutler Group LP1,200$3.00K0.00%

Sold out (22)

Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.